P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA

P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA

Detalhes bibliográficos
Principais autores:	J. McCloskey, V. Pullarkat, G. Mannis, T. L. Lin, S. A. Strickland, A. T. Fathi, H. P. Erba, S. Faderl, D. Chakravarthy, Y. Lutska, V. Chandrasekaran, R. S. Cheung, M. Levis
Formato:	Artigo
Idioma:	English
Publicado em:	Wiley 2022-06-01
coleção:	HemaSphere
Acesso em linha:	http://journals.lww.com/10.1097/01.HS9.0000844944.65720.85

Registros relacionados

CPX-351 in FLT3-mutated acute myeloid leukemia
por: Claire Andrews, et al.
Publicado em: (2023-11-01)

P515: LOWER-INTENSITY CPX-351 + VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY
por: G. L. Uy, et al.
Publicado em: (2022-06-01)

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy
por: Geoffrey L. Uy, et al.
Publicado em: (2024-12-01)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
por: Joshua D. Mitchell, et al.
Publicado em: (2023-08-01)

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
por: Romane Joudinaud, et al.
Publicado em: (2025-01-01)

Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report
por: Kasey J. Leger, et al.
Publicado em: (2024-06-01)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Katja Seipel, et al.
Publicado em: (2018-11-01)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
por: Frank G. Rücker, et al.
Publicado em: (2024-12-01)

FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
por: Pierre Peterlin, et al.
Publicado em: (2024-11-01)

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
por: Denise Wolleschak, et al.
Publicado em: (2014-06-01)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia
por: Julia S. Lee, et al.
Publicado em: (2023-06-01)

Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
por: Qian Yan, et al.
Publicado em: (2025-01-01)

P574: CPX-351 COMBINED WITH HEMATOPOIETIC CELL TRANSPLANTATION WITH REGULATORY AND CONVENTIONAL T CELL IMMUNOTHERAPY FOR HIGH-RISK ACUTE MYELOID LEUKEMIA
por: S. Sciabolacci, et al.
Publicado em: (2022-06-01)

Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
por: Pierre Peterlin, et al.
Publicado em: (2025-01-01)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Mar Tormo, et al.
Publicado em: (2023-08-01)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
por: Marie C. Fortin, et al.
Publicado em: (2023-11-01)

P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).
por: B. Garibaldi, et al.
Publicado em: (2022-06-01)

Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemiaResearch in context
por: Weronika E. Borek, et al.
Publicado em: (2024-10-01)

P523: MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY IN FLT3 MUTATED AML. “REAL LIFE” DATA VERSUS THE RATIFY STUDY
por: A. De La Fuente, et al.
Publicado em: (2022-06-01)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
por: Hiroaki Araie, et al.
Publicado em: (2023-08-01)

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
por: Pierantonio Menna, et al.
Publicado em: (2023-10-01)

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
por: Thomas Cluzeau, et al.
Publicado em: (2025-02-01)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
por: Anjali Cremer, et al.
Publicado em: (2023-08-01)

P508: REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY.
por: T. Bernal, et al.
Publicado em: (2022-06-01)

S128: A RANDOMISED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA. RESULTS FROM THE NCRI AML19 TRIAL
por: N. Russell, et al.
Publicado em: (2022-06-01)

P513: CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: REAL-WORLD OUTCOMES IN ADULTS AGED <60 YEARS VERSUS ≥60 YEARS
por: A. Legg, et al.
Publicado em: (2022-06-01)

P539: PROGNOSTIC RELEVANCE OF MINIMAL RESIDUAL DISEASE IN THERAPY RELATED AND SECONDARY ACUTE MYELOID LEUKEMIA RECEIVING CPX-351 OR FLUDARABINE-BASED INDUCTION.
por: F. Guolo, et al.
Publicado em: (2022-06-01)

Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
por: Karam Ashouri, et al.
Publicado em: (2024-04-01)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Arran Dokal, et al.
Publicado em: (2023-08-01)

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study
por: Chiara Cattaneo, et al.
Publicado em: (2022-05-01)

The current therapeutic landscape of FLT3 inhibitors
por: Mark Levis
Publicado em: (2017-10-01)

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
por: Teresa Bernal, et al.
Publicado em: (2023-07-01)

PB1879: EFFICACY AND SAFETY OF CPX-351 COMPARED TO STANDARD OF CARE CHEMOTHERAPY IN A REAL-LIFE SETTING: SUPPORTING PREVIOUS EVIDENCE AND FACING NEW CHALLENGES
por: Beatrice Manghisi, et al.
Publicado em: (2023-08-01)

Sorafenib maintenance after allogeneic stem cell transplantation in patients with FLT3+ AML receiving midostaurin during induction and consolidation: a retrospective analysis
por: Giuseppe Sapienza, et al.
Publicado em: (2024-09-01)

P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON
por: E. N. Oliva, et al.
Publicado em: (2022-06-01)

S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL
por: N. Russell, et al.
Publicado em: (2022-06-01)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
por: Gian Luca Morelli, et al.
Publicado em: (2023-08-01)

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for <i>FLT3</i>- mutated acute myeloid leukemia patients – Czech center experience
por: Barbora Weinbergerová, et al.
Publicado em: (2023-02-01)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
por: Carolin Joisten, et al.
Publicado em: (2023-08-01)

Regulatory role of the Cpx ESR in bacterial behaviours
por: Jiajia Wan, et al.
Publicado em: (2024-12-01)